CRISPR Therapeutics AG (CRSP)

Industry Biotechnology

This stock can be held in an Investment ISA and an Investment Account

Sell

$50.52

Buy

$50.80

arrow-down$-0.84 (-1.63%)

Prices updated at 13 Oct 2026, 15:01 EDT

Prices minimum 15 mins delay

Prices in USD

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolu ...

NASDAQ

0.1%

NASDAQ

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

our Investment Fees and Charges.

	$51.11 - $50.05
	$75.06 - $44.12
	-
	4,984.51m
	-
	-
	186,724
	2.85
	1,864,728.62
	3.37
	96.01m
	CH0334081137
	-6.47
	-

Please note that past performance is not a reliable indicator of future returns. Pre-sale Illustration.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser.

© Copyright 2026 Morningstar. All rights reserved. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

The ESG-related information, methodologies, tools, ratings, data and opinions contained or reflected herein are not directed to or intended for use or distribution to India-based clients or users and their distribution to Indian resident individuals or entities is not permitted, and Morningstar accepts no responsibility or liability whatsoever for the actions of third parties in this respect.